Skip to main navigation Skip to search Skip to main content

The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

  • GBD 2017 Pancreatic Cancer Collaborators
  • Tehran University of Medical Sciences
  • Shiraz University of Medical Sciences
  • University of Washington
  • Tabriz University of Medical Sciences
  • Golestan University of Medical Sciences
  • Islamic Azad University
  • McGill University
  • Baku State University
  • Duke University
  • Mayo Clinic Rochester, MN
  • Iran University of Medical Sciences
  • Mansoura University
  • Health Promotion Research Center (ZAUMS)
  • Public Health Agency of Canada
  • University of Toronto
  • Sharif University of Technology
  • Wollo University
  • Gondar University
  • Babol University of Medical Sciences
  • University of Catania
  • University of Bergen
  • Cancer Registry of Norway Institute of Population-Based Cancer Research
  • IRCCS Istituto di ricerche farmacologiche Mario Negri - Milano, Bergamo, Ranica
  • Bauman Moscow State Technical University
  • Sechenov First Moscow State Medical University
  • Institute for the Study and Prevention of Cancer
  • University of Porto
  • Seoul National University
  • Hanoi National University of Education
  • Duy Tan University
  • Mazandaran University of Medical Sciences
  • Carol Davila University of Medicine and Pharmacy
  • Clinical Emergency Hospital Sf. Pantelimon
  • Aksum University
  • Addis Ababa University
  • Department of Veterans Affairs
  • Disha Foundation
  • Nguyen Tat Thanh University
  • Maragheh University of Medical Sciences
  • Kaiser Permanente
  • Kirksville College of Osteopathic Medicine
  • Qatar Foundation HQ
  • Bielefeld University
  • Abadan University of Medical Sciences
  • Cleveland Clinic Foundation
  • University of North Carolina at Chapel Hill
  • Prevention and Research Institute
  • Johns Hopkins University
  • Guilan University of Medical Sciences
  • Adigrat University
  • National Institute of Legal Medicine Mina Minovici
  • University of Ibadan
  • University of Kragujevac
  • Shahid Beheshti University of Medical Sciences
  • Babol Noshirvani University of Technology
  • Mekelle University
  • South African Medical Research Council
  • University of Cape Town
  • Health Services Academy
  • National Hepatology and Tropical Research Institute
  • Kermanshah University of Medical Sciences
  • Fred Hutchinson Cancer Research Center
  • Neurophysiology Research Center
  • Institute for Research for Fundamental Sciences
  • San Juan de Dios Sanitary Park
  • ICREA
  • Harvard University
  • A.C.S. Medical College and Hospital
  • University of Manitoba
  • New York Medical College
  • Seven Hills Hospital
  • Martin Luther University Halle-Wittenberg
  • Innovation Office
  • Haramaya University
  • Pomeranian Medical University in Szczecin
  • Shahrekord University of Medical Sciences
  • Tarbiat Modarres University
  • Ahmadu Bello University
  • Heidelberg University 
  • IRCCS Ospedale Infantile Burlo Garofolo - Trieste
  • Birjand University of Medical Sciences
  • Arak University of Medical Sciences
  • University of Alabama at Birmingham
  • McMaster University
  • University of Lagos
  • Amirkabir University of Technology
  • Medichem S.A.
  • All India Institute of Medical Sciences, New Delhi
  • Imperial College London
  • University College London Hospitals NHS Foundation Trust
  • UK Health Security Agency
  • Universal Scientific Education and Research Network (USERN)
  • Ain Shams University
  • Mashhad University of Medical Sciences
  • Marshall University
  • Case Western Reserve University
  • University of North Carolina at Charlotte
  • University of Zagreb
  • Croatian National Institute of Public Health
  • Russian Academy of Medical Sciences - N.N. Blokhin Russian Cancer Research Center
  • Independent Consultant
  • Delhi Technological University
  • Baystate Medical Center
  • Stavanger University Hospital
  • Research Development Department
  • Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation
  • University of Valencia
  • Hanoi Medical University
  • The University of Auckland
  • Vietnam Military Medical University
  • Gomal University
  • Mufti Mehmood Memorial Teaching Hospital
  • Baqiyatallah Medical Sciences University
  • Central Research Institute of Cytology and Genetics
  • Federal Institute for Population Research
  • National Center of Neurology and Psychiatry Kodaira
  • Institute of Oncology Ljubljana
  • Wuhan University

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Worldwide, both the incidence and death rates of pancreatic cancer are increasing. Evaluation of pancreatic cancer burden and its global, regional, and national patterns is crucial to policy making and better resource allocation for controlling pancreatic cancer risk factors, developing early detection methods, and providing faster and more effective treatments. Methods: Vital registration, vital registration sample, and cancer registry data were used to generate mortality, incidence, and disability-adjusted life-years (DALYs) estimates. We used the comparative risk assessment framework to estimate the proportion of deaths attributable to risk factors for pancreatic cancer: smoking, high fasting plasma glucose, and high body-mass index. All of the estimates were reported as counts and age-standardised rates per 100 000 person-years. 95% uncertainty intervals (UIs) were reported for all estimates. Findings: In 2017, there were 448 000 (95% UI 439 000–456 000) incident cases of pancreatic cancer globally, of which 232 000 (210 000–221 000; 51·9%) were in males. The age-standardised incidence rate was 5·0 (4·9–5·1) per 100 000 person-years in 1990 and increased to 5·7 (5·6–5·8) per 100 000 person-years in 2017. There was a 2·3 times increase in number of deaths for both sexes from 196 000 (193 000–200 000) in 1990 to 441 000 (433 000–449 000) in 2017. There was a 2·1 times increase in DALYs due to pancreatic cancer, increasing from 4·4 million (4·3–4·5) in 1990 to 9·1 million (8·9–9·3) in 2017. The age-standardised death rate of pancreatic cancer was highest in the high-income super-region across all years from 1990 to 2017. In 2017, the highest age-standardised death rates were observed in Greenland (17·4 [15·8–19·0] per 100 000 person-years) and Uruguay (12·1 [10·9–13·5] per 100 000 person-years). These countries also had the highest age-standardised death rates in 1990. Bangladesh (1·9 [1·5–2·3] per 100 000 person-years) had the lowest rate in 2017, and São Tomé and Príncipe (1·3 [1·1–1·5] per 100 000 person-years) had the lowest rate in 1990. The numbers of incident cases and deaths peaked at the ages of 65–69 years for males and at 75–79 years for females. Age-standardised pancreatic cancer deaths worldwide were primarily attributable to smoking (21·1% [18·8–23·7]), high fasting plasma glucose (8·9% [2·1–19·4]), and high body-mass index (6·2% [2·5–11·4]) in 2017. Interpretation: Globally, the number of deaths, incident cases, and DALYs caused by pancreatic cancer has more than doubled from 1990 to 2017. The increase in incidence of pancreatic cancer is likely to continue as the population ages. Prevention strategies should focus on modifiable risk factors. Development of screening programmes for early detection and more effective treatment strategies for pancreatic cancer are needed. Funding: Bill & Melinda Gates Foundation.

Original languageEnglish
Pages (from-to)934-947
Number of pages14
JournalThe Lancet Gastroenterology and Hepatology
Volume4
Issue number12
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Dive into the research topics of 'The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017'. Together they form a unique fingerprint.

Cite this